Finance

Lists
Q2 2026 earnings • released • EPS beat +3,384.35% • Revenue beat +36.61%
See results
ANAB:NASDAQ
AnaptysBio Inc
$51.70
+1.83%
(+0.93) 1D
$52.21
+0.99% (+0.51)
After hours
Closed: Sep 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANAB...
Open
$50.59
High
$52.16
Low
$50.35
Mkt. cap
1.53B
Avg. vol.
467.14K
Volume
418.40K
52-wk high
$72.36
52-wk low
$13.86
EPS
-$0.88
Beta
0.40
Shares outstanding
29.90M
No. of employees
104
Open
$50.59
High
$52.16
Low
$50.35
Mkt. cap
1.53B
Avg. vol.
467.14K
Volume
418.40K
52-wk high
$72.36
52-wk low
$13.86
EPS
-$0.88
Beta
0.40
Shares outstanding
29.90M
No. of employees
104
News stories
From web sources and news partners
About AnaptysBio Inc
CEO-
Employees104
Founded2005
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteanaptysbio.com
Analyst ratings
Based on 6 analysts giving stock ratings to ANAB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ANAB in the last 3 months.
Highest
Current $51.70
$95.00 (+83.75%)
Average
$84.00 (+62.48%)
Lowest
$75.00 (+45.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Risinger
Leerink Partners
Buy
Maintained
$81.00
+56.7%
09/23/2026
Etzer Darout
Barclays
Buy
Maintained
$75.00
+45.1%
09/22/2026
Michael Yee
UBS
Buy
Reiterated
$76.00
+47%
09/22/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$95.00
+83.8%
09/22/2026
Joseph Thome
TD Cowen
Buy
Reiterated
-
-
08/25/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+79.9%
07/21/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$70.00
+35.4%
05/22/2026
David Nierengarten
Wedbush
Buy
Reiterated
$75.00
+45.1%
03/31/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$66.00
+27.7%
03/30/2026
Joon Lee
Truist Financial
Hold
Maintained
$50.00
-3.3%
03/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$85.00
+64.4%
03/05/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$140.00
+170.8%
03/04/2026
Last report
Sep 21, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.93 / $0.14
+3,384.35%beat
Revenue / Est. (USD)
27.49M / 20.12M
+36.61%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
22.26M
76.32M
108.25M
25.56M
Cost of goods sold
37.82M
31.41M
25.56M
33.99M
Cost of revenue
37.82M
31.41M
25.56M
33.99M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.61M
10.21M
15.79M
26.20M
Operating expense
10.61M
10.21M
15.79M
26.20M
Total operating expenses
48.43M
41.62M
41.35M
60.19M
Operating income
-26.17M
34.70M
66.90M
-34.64M
Other non operating income
3.53M
-
-5.43M
-1.00K
EBT including unusual items
-38.59M
15.11M
49.70M
-52.84M
EBT excluding unusual items
-38.59M
15.11M
49.70M
-52.84M
Income tax expense
39.00K
-
81.00K
40.00K
Effective tax rate
-0.10%
-
0.16%
-0.08%
Other operating expenses
-
-
-
-
Net income
-38.63M
15.11M
49.61M
-52.88M
Net profit margin
-173.52%
19.80%
45.83%
-206.93%
Earnings per share
-1.34
0.52
1.58
-1.84
Interest and investment income
3.65M
2.92M
2.51M
2.65M
Interest expense
-19.61M
-22.52M
-19.71M
-20.86M
Net interest expenses
-15.95M
-19.59M
-17.20M
-18.21M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.03M
34.84M
67.03M
-34.51M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps